On behalf of Genentech, Inc., I respectfully request the NCCN NHL Guideline Panel to review the enclosed recent key publications for:

- **Rituxan** (rituximab): Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL) and Follicular NHL
  

**Specific Changes:**

- **Rituxan**: Results from the pivotal Phase III RATE study were previously submitted and are now published in the Leukemia & Lymphoma journal.

**FDA Clearance:**

- **Rituxan** is On-label for Previously Untreated DLBCL and Follicular NHL of NHL

Please refer to the enclosed prescribing information for the full FDA-approved indications and safety information.

**Rationale:**

- **Rituxan**: Results from the pivotal Phase III RATE study were previously submitted\(^1\) and are now published in the Leukemia & Lymphoma journal.

Respectfully submitted,

[Signature]

**Supplemental References**